Looking to expand beyond diabetes, Novo Nordisk enlists Evotec in CKD pact worth up to $179M per program
Most of Novo Nordisk’s kidney work has come from diabetes, but eyeing an R&D expansion, the Danish giant is putting money down on a pact to target chronic kidney disease directly.
The new deal comes with an old partner: the German drug discovery company Evotec. Under the agreement, Evotec and Novo will collaborate on discovering and developing pre-clinical candidates across different modalities for CKD. Novo will then be in charge of clinical and commercial development for any promising approaches.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
